AWMSG advice
Rituximab (MabThera®) solution for subcutaneous injection is recommended as an option for use within NHS Wales for the treatment of adults for non-Hodgkin's lymphoma (NHL): for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy; as maintenance therapy for the treatment of follicular lymphoma patients responding to induction therapy; and for the treatment of patients with CD20-positive diffuse large B cell NHL in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.
